The DOI matches its Crossref record; 306 of the 306 references it cites were found in a registry or an index.
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
Open accessAbstract
These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–306 of 306
Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations
Gazdar, A. F., Robinson, L. D., Oliver, D., Xing, C., Travis, W. D., Soh, J., Toyooka, S., Watumull, L. M., Xie, Y., Kernstine, K. H., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000130 · Cited by 156
Thornton, K. A., Kim, G., Maher, V. E., Chattopadhyay, S., Tang, S. W., Moon, Y. J., Song, P., Marathe, A., Balakrishnan, S., Zhu, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0411 · Cited by 152
Chow, S., Yau, S. S. ‐., Kwan, C.-K., Poon, P. C. M., & Law, S. C. K. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01320 · Cited by 151
Markman, M. M., Zanotti, K. M., Peterson, G., Kulp, B., Webster, K. D., & Belinson, J. L. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.539 · Cited by 150
Landrum, L. M., Java, J., Mathews, C. A., Lanneau, G. S., Copeland, L. J., Armstrong, D. K., & Walker, J. L. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.04.001 · Cited by 149
Lim, S., Chang, H. K., Yoon, M. J., Hong, Y. K., Kim, H., Chung, W. Y., Park, C. S., Nam, K., Kang, S., Kim, M. K., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt379 · Cited by 147
Cerci, J. J., Pracchia, L. F., Linardi, C. C. G., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.073197 · Cited by 146
Terezakis, S. A., Lee, K. S., Ghossein, R. A., Rivera, M., Tuttle, R. M., Wolden, S. L., Zeléfsky, M. J., Wong, R. J., Patel, S. G., Pfister, D. G., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.05.012 · Cited by 143
Cytotoxic Chemotherapy for Differentiated Thyroid Carcinoma
Sherman, S. I. (2010) · Clinical Oncology · doi:10.1016/j.clon.2010.03.014 · Cited by 142
Piana, S., Frasoldati, A., Felice, E. D., Gardini, G., Tallini, G., & Rosaí, J. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181dbee07 · Cited by 141
Gadducci, A., Carnino, F., Chiara, S., Brunetti, I. M., Tanganelli, L., Romanini, A., Bruzzone, M., & Conte, P. (2000) · Gynecologic Oncology · doi:10.1006/gyno.1999.5677 · Cited by 140
Burtness, B. A., Anadkat, M. J., Basti, S., Hughes, M., Lacouture, M. E., McClure, J. S., Myskowski, P. L., Jennifer, P., Perlis, C., Saltz, L. B., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0074 · Cited by 135
Self-citationLetrozole in the neoadjuvant setting: the P024 trial
Ellis, M. J., & Ma, C. X. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9701-x · Cited by 133
Villaruz, L. C., Socinski, M. A., Abberbock, S. R., Berry, L. D., Johnson, B. E., Kwiatkowski, D. J., Iafrate, A. J., Varella‐Garcia, M., Franklin, W. A., Camidge, D. R., et al. (2014) · Cancer · doi:10.1002/cncr.29042 · Cited by 130
Self-citationSchneider, T., Abdulrahman, R. M., Corssmit, E. P. M., Morreau, H. M., Smit, J. W. A., & Kapiteijn, E. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0405 · Cited by 130
ALK Status Testing in Non–Small Cell Lung Carcinoma
Minca, E. C., Portier, B. P., Wang, Z., Lanigan, C. P., Farver, C. F., Feng, Y., Ma, P. C., Arrossi, V., Pennell, N. A., & Tubbs, R. R. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.01.004 · Cited by 122
Locati, L. D., Licitra, L. F., Agate, L., Ou, S. I., Boucher, A., Jarząb, B., Qin, S., Kane, M. A., Wirth, L. J., Chen, C., et al. (2014) · Cancer · doi:10.1002/cncr.28766 · Cited by 121
Physician factors in the timing of cancer patient referral to hospice palliative care
Lamont, E. B., & Christakis, N. A. (2002) · Cancer · doi:10.1002/cncr.10530 · Cited by 121
Opportunistic infections in patients treated with immunotherapy for cancer
Kyi, C., Hellmann, M. D., Wolchok, J. D., Chapman, P. B., & Postow, M. A. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-19 · Cited by 120
Vitale, G., Fonderico, F., Martignetti, A., Caraglia, M., Ciccarelli, A., Nuzzo, V., Abbruzzese, A., & Lupoli, G. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1832 · Cited by 119
Ethical Dilemmas and Moral Distress in Oncology Nursing Practice
Cohen, J. S., & Erickson, J. M. (2006) · Clinical journal of oncology nursing · doi:10.1188/06.cjon.775-780 · Cited by 118
Sholl, L. M., Xiao, Y., Joshi, V. A., Yeap, B. Y., Cioffredi, L., Jackman, D. M., Lee, C., Janne, P. A., & Lindeman, N. I. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpst1cthzs3psz · Cited by 117
Expectations About the Effectiveness of Radiation Therapy Among Patients With Incurable Lung Cancer
Chen, A. B., Cronin, A. M., Weeks, J. C., Chrischilles, E. A., Malin, J. K., Hayman, J. A., & Schrag, D. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5748 · Cited by 116
van Vliet, L. M., van der Wall, E., Plum, N., & Bensing, J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.5865 · Cited by 114
Colombo, P., Mourrégot, A., Fabbro, M., Gutowski, M., Saint‐Aubert, B., Quénet, F., Gourgou, S., & Rouanet, P. (2008) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2008.01.005 · Cited by 113
The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer
Cardarella, S., Ortiz, T. M., Joshi, V. A., Butaney, M., Jackman, D. M., Kwiatkowski, D. J., Yeap, B. Y., Janne, P. A., Lindeman, N. I., & Johnson, B. E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745bcb · Cited by 112
Chemotherapy in Metastatic Nonanaplastic Thyroid Cancer: Experience at the Institut Gustave-Roussy
Droz, J., Schlumberger, M. J., Rougier, P. R., Ghosn, M., Gardet, P., & Parmentier, C. (1990) · Tumori Journal · doi:10.1177/030089169007600513 · Cited by 110
A Detailed Clinicopathologic Study of ALK-translocated Papillary Thyroid Carcinoma
Chou, A. S. Y., Fraser, S., Toon, C. W., Clarkson, A., Sioson, L., Farzin, M., Cussigh, C., Aniss, A. M., O’Neill, C. J., Watson, N., et al. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000368 · Cited by 110
Communication in palliative care: a review of recent literature
de Haes, J. C. J. M., & Teunissen, S. C. C. M. (2005) · Current Opinion in Oncology · doi:10.1097/01.cco.0000167735.26454.79 · Cited by 108
Dramatic Response Induced by Vemurafenib in a BRAF V600E-Mutated Lung Adenocarcinoma
Peters, S., Michielin, O. A., & Zimmermann, S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.6143 · Cited by 106
Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers
Sherman, S. I. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0923 · Cited by 105
Massicotte, M.-H., Brassard, M., Claude-Desroches, M., Borget, I., Bonichon, F., Giraudet, A., Cao, C. D., Chougnet, C., Leboulleux, S., Baudin, É., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0825 · Cited by 105
The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers
Atherly, A. J., & Camidge, D. R. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.60 · Cited by 104
Self-citationRole of pegylated liposomal doxorubicin in ovarian cancer
Thigpen, J. T., Aghajanian, C. A., Alberts, D. S., Campos, S. M., Gordon, A. N., Markman, M. M., McMeekin, D. S., Monk, B. J., & Rose, P. G. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.09.046 · Cited by 102
Vandenput, I., CALSTER, B. V., Capoen, A., Leunen, K., Berteloot, P., Neven, P., Moerman, P., Vergote, I. B., & Amant, F. C. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605157 · Cited by 97
McNamara, B. A., Rosenwax, L. K., Murray, K. J., et al. (2013) · Journal of Palliative Medicine · doi:10.1089/jpm.2012.0403 · Cited by 95
Ovarian cancer: the duplicity of CA125 measurement
Karam, A., & Karlan, B. Y. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.44 · Cited by 95
Sgambato, A., Casaluce, F., Sacco, P. C., Palazzolo, G., Maione, P., Rossi, A., Ciardiello, F., & Gridelli, C. (2015) · Current Drug Safety · doi:10.2174/1574886311207040289 · Cited by 94
New treatment modalities in advanced thyroid cancer
Kapiteijn, E., Schneider, T., Morreau, H. M., Gelderblom, H. A. J., Nortier, J. W. R., & Smit, J. W. A. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr117 · Cited by 91
Review: Practical considerations in ovarian cancer chemotherapy
Cristea, M. C., Han, E. S., Salmon, L., & Morgan, R. J. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010361333 · Cited by 89
Weickhardt, A. J., Aisner, D. L., Franklin, W. A., Varella‐Garcia, M., Doebele, R. C., & Camidge, D. R. (2012) · Cancer · doi:10.1002/cncr.27913 · Cited by 88
Self-citationCarhill, A. A., Cabanillas, M. E., Jiménez, C., Waguespack, S. G., Habra, M. A., Hu, M. I.-N., Ying, A. K., Vassilopoulou‐Sellin, R., Gagel, R. F., Sherman, S. I., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2909 · Cited by 88
Alì, G., Proietti, A., Pelliccioni, S., Niccoli, C., Lupi, C., Sensi, E., Giannini, R., Borrelli, N., Menghi, M., Chella, A., et al. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0388-oa · Cited by 87
Jiang, X. “., Harrison, G. P., & Datto, M. (2016) · Cancer Cytopathology · doi:10.1002/cncy.21802 · Cited by 87
Targeted therapies for thyroid tumors
Sherman, S. I. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.165 · Cited by 86
Gwilliam, B., Keeley, V. L., Todd, C. J., Roberts, C., Gittins, M., Kelly, L., Barclay, S. I. G., & Stone, P. C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds341 · Cited by 85
Shah, M. H., Wei, L., Wirth, L. J., Daniels, G. A., de Souza, J. A., Timmers, C. D., Sexton, J., Beshara, M., Nichols, D., Snyder, N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.6022 · Cited by 85
Germline EGFR T790M Mutation Found in Multiple Members of a Familial Cohort
Yu, H. A., Arcila, M. E., Fleischut, M. H., Stadler, Z. K., Ladanyi, M., Berger, M. F., Robson, M. E., & Riely, G. J. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000052 · Cited by 82
Self-citationPalliative care reduces morbidity and mortality in cancer
Rocque, G. B., & Cleary, J. F. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.211 · Cited by 80
Barriers and Approaches to the Successful Integration of Palliative Care and Oncology Practice
Roenn, J. H. V., Voltz, R., & Serrié, A. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0209 · Cited by 79
von Laffert, M., Warth, A., Penzel, R., Schirmacher, P., Kerr, K. M., Elmberger, G., Schildhaus, H., Büttner, R., López‐Ríos, F., Reu, S., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000332 · Cited by 76
Morita, T., Miyashita, M., Tsuneto, S., Sato, K., & Shima, Y. (2009) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2008.09.011 · Cited by 74
Vergote, I. B., Trope, C. G., Amant, F. C., Ehlen, T., Reed, N. S., & Casado, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9785 · Cited by 74
CA 125 and the detection of recurrent ovarian cancer
Bast, R. C. (2010) · Cancer · doi:10.1002/cncr.25203 · Cited by 73
NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network.
Ettinger, D. S., Cox, J. D., Ginsberg, R. J., Komaki, R. U., Kris, M. G., Livingston, R. B., & Sugarbaker, D. J. (1996) · PubMed · Cited by 71
Self-citationGriffiths, R. W., Zee, Y.-K., Evans, S., Mitchell, C. L., Kumaran, G., Welch, R., Jayson, G. C., Clamp, A. R., & Hasan, J. (2010) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e3182049273 · Cited by 70
Anderson, R. T., Linnehan, J. E., Tongbram, V., Keating, K. N., & Wirth, L. J. (2013) · Thyroid · doi:10.1089/thy.2012.0520 · Cited by 70
Hesselink, E. N. K., Steenvoorden, D. P. T., Kapiteijn, E., Corssmit, E. P. M., van der Horst‐Schrivers, A. N. A., Lefrandt, J. D., Links, T. P., & Dekkers, O. M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0788 · Cited by 70
Advances in immunotherapy for treatment of lung cancer.
Alvarez, J. G. B., González‐Cao, M., Karachaliou, N., Santarpía, M., Viteri, S., Teixidó, C., & Rosell, R. (2015) · PubMed Central · doi:10.7497/j.issn.2095-3941.2015.0032 · Cited by 68
Talking with Patients about Dying
Smith, T. J., & Longo, D. L. (2012) · New England Journal of Medicine · doi:10.1056/nejme1211160 · Cited by 67
Bhosale, P., Peungjesada, S., Wei, W., Levenback, C. F., Schmeler, K. M., ROHREN, E. M., Macapinlac, H. A., & Iyer, R. B. (2010) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181e82a7f · Cited by 65
Carboplatin dosing in obese women with ovarian cancer: A Gynecologic Oncology Group study
Wright, J. D., Tian, C., Mutch, D. G., Herzog, T. J., Nagao, S., Fujiwara, K., & Powell, M. A. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.02.023 · Cited by 64
Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy
Chapman, P. B., D’Angelo, S. P., & Wolchok, J. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1501894 · Cited by 63
Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer
Petrelli, F., Borgonovo, K., Cabiddu, M., Ghilardi, M., & Barni, S. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32834120aa · Cited by 63
Clinicopathological Characteristics of 11 NSCLC Patients with EGFR-Exon 20 Mutations
Lund‐Iversen, M., Kleinberg, L., Fjellbirkeland, L., Helland, Å., & Brustugun, O. T. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182614a9d · Cited by 63
Jeurkar, N., Farrington, S., Craig, T. R., Slattery, J., Harrold, J. K., Oldanie, B., Teno, J. M., & Casarett, D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5711 · Cited by 63
Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies
Mantia-Smaldone, Edwards, & Vlad, A. (2010) · Cancer Management and Research · doi:10.2147/cmar.s8759 · Cited by 63
Ten Years of Progress in Non–Small Cell Lung Cancer
Ettinger, D. S. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0029 · Cited by 63
Self-citationOzols, R. F., Bookman, M. A., du Bois, A., Pfisterer, J., Reuß, A., & Young, R. C. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.06.026 · Cited by 62
BRAFV600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas
Takano, T., Ito, Y., Hirokawa, M., Yoshida, H., & Miyauchi, A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603764 · Cited by 60
Risum, S., Roed, H., Engelholm, S. A., Høgdall, C. K., Markova, E., Berthelsen, A. K., Loft, A., Jensen, F., & Høgdall, E. V. S. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181a3cc94 · Cited by 59
Aggressive Palliation and Survival in Anaplastic Thyroid Carcinoma
Nachalon, Y., Shavit, S. S., Bachar, G. Y., Shvero, J., Limon, D., & Popovtzer, A. (2015) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2015.2332 · Cited by 55
Đačić, S. (2008) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31817bf5a9 · Cited by 53
Cohen, E. E. W., Tortorici, M. A., Kim, S., Ingrosso, A., Pithavala, Y. K., & Bycott, P. W. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2604-8 · Cited by 52
Intraperitoneal Therapy for Ovarian Cancer: A Treatment Ready for Prime Time
Armstrong, D. K., & Brady, M. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7140 · Cited by 52
Late Referrals to Palliative Care
FERRELL, B. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.908 · Cited by 50
Advanced ovarian cancer: what should be the standard of care?
Goff, B. A. (2013) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2013.24.1.83 · Cited by 48
Advani, R. H., Maeda, L. S., Lavori, P. W., Quon, A. S. W., Hoppe, R. T., Breslin, S., Rosenberg, S. A., & Horning, S. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9867 · Cited by 46
Scarpace, S. L. (2015) · Drugs in Context · doi:10.7573/dic.212289 · Cited by 46
Manivannan, V., Decker, W. W., Ganti, L., Li, J. T. C., & Campbell, R. L. (2009) · International Journal of Emergency Medicine · doi:10.1007/s12245-009-0093-z · Cited by 43
Lassalle, S., Hofman, V., Ilié, M., Butori, C., Bozec, A., Santini, J., Vielh, P. R., & Hofman, P. M. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791111189 · Cited by 42
Kao, C., Wang, H., Tang, S.-C., Huang, K., Jaing, T., Liu, C., Keng-Hao, L., Shen, W., Wu, J., Hung, Y., et al. (2013) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2013.03.020 · Cited by 41
Cañadas‐Garre, M., Becerra‐Massare, P., de la Torre-Casares, M. L., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31824e8d70 · Cited by 41
Neoadjuvant Treatment of Unresectable Medullary Thyroid Cancer With Sunitinib
Cleary, J. M., Sadow, P. M., Randolph, G. W., Palmer, E. L., Lynch, T. J., Nikiforov, Y. E., & Wirth, L. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4225 · Cited by 40
Advances in immunotherapy for treatment of lung cancer
Jean, Bustamante, Álvarez, et al. (2015) · 癌症生物学与医学:英文版 · Cited by 40
Response to Sunitinib in Medullary Thyroid Cancer
Kelleher, F. C., & McDermott, R. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-7-200804010-00027 · Cited by 38
Matrana, M. R., Duran, C., Shetty, A., Xiao, L., Atkinson, B. J., Corn, P. G., Pagliaro, L. C., Millikan, R. E., Charnsangave, C., Jonasch, E. W., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.003 · Cited by 38
Vansteenkiste, J., Fehrenbacher, L., Spira, A. I., Mazières, J., Park, K., Smith, D. A., Artal, A., Lewanski, C. R., Braiteh, F., Yi, J., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(15)30072-1 · Cited by 36
The American Society of Clinical Oncology Program to Improve End-of-Life Care
Smith, T. J., & Schnipper, L. J. (1998) · Journal of Palliative Medicine · doi:10.1089/jpm.1998.1.221 · Cited by 35
Evolving Approaches in Managing Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Sacks, W. L., & Braunstein, G. D. (2013) · Endocrine Practice · doi:10.4158/ep13305.ra · Cited by 32
Big Costs for Little Gain in Ovarian Cancer
Hensley, M. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.0489 · Cited by 32
Markman, M. M. (2011) · Cancer Management and Research · doi:10.2147/cmar.s15558 · Cited by 31
New therapeutic options for advanced forms of thyroid cancer
Bernet, V. J., & Smallridge, R. C. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.894017 · Cited by 30
End-of-Life Issues in Critically Ill Cancer Patients
Gaeta, S., & Price, K. (2009) · Critical Care Clinics · doi:10.1016/j.ccc.2009.10.002 · Cited by 29
Fujiwara, K., Nagao, S., Kigawa, J., Noma, J., Akamatsu, N., Miyagi, Y., Numa, F., Okada, M., & Aotani, E. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181a29dfe · Cited by 28
Cabozantinib approved for advanced medullary thyroid cancer
Traynor, K. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/news130005 · Cited by 28
An update on clinical trials of targeted therapies in thyroid cancer
Haraldsdóttir, S., & Shah, M. H. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000029 · Cited by 27
Ovarian Cancer: Opportunity for Targeted Therapy
Tagawa, T., Morgan, R. J., Yen, Y., & Mortimer, J. E. (2011) · Journal of Oncology · doi:10.1155/2012/682480 · Cited by 26
Weickhardt, A. J., & Camidge, D. R. (2011) · Clinical Investigation · doi:10.4155/cli.11.92 · Cited by 22
Self-citationFurber, L., Cox, K., Murphy, R., & Steward, W. P. (2013) · European Journal of Cancer Care · doi:10.1111/ecc.12074 · Cited by 21
Investigational Therapies for Metastatic Thyroid Carcinoma
Tuttle, R. M., & Leboeuf, R. (2007) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2007.0055 · Cited by 20
Communicating a prognosis in advanced cancer.
Sinclair, C. T. (2006) · PubMed · Cited by 20
Three ongoing intraperitoneal chemotherapy trials in ovarian cancer
Fujiwara, K. (2012) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2012.23.2.75 · Cited by 19
Ovarian cancer: relevant therapy, not timing, is paramount
Morris, R. T., & Monk, B. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61515-2 · Cited by 18
Advani, R. H., Hoppe, R. T., Maeda, L. S., Baer, D. M., Mason, J., Rosenberg, S. A., & Horning, S. J. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.07.041 · Cited by 13
Targeted Treatment of Differentiated and Medullary Thyroid Cancer
Bales, S. R., & CHOPRA, I. J. (2011) · Journal of Thyroid Research · doi:10.4061/2011/102636 · Cited by 8
Cited by
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Self-citationAppio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
Chun, S. G., Hu, C., Choy, H., Komaki, R. U., Timmerman, R. D., Schild, S. E., Bogart, J. A., Dobelbower, M. C., Bosch, W., Galvin, J. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.1378 · Cited by 746
Self-citationThe current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Zhong, W.-Z., Wang, Q., Mao, W.-M., Xu, S.-T., Wu, L., Shen, Y., Liu, Y.-Y., Chen, C., Cheng, Y., Xu, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30729-5 · Cited by 529
Metadata
- Authors
- Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., Dobelbower, M. C., Govindan, R., Hennon, M., Horn, L., Jahan, T. M., Komaki, R., Lackner, R. P., Lanuti, M., Lilenbaum, R., Lin, J., Loo, B. W., Martins, R., Otterson, G. A., Patel, J. D., Pisters, K. M., Reckamp, K., Riely, G. J., Schild, S. E., Shapiro, T. A., Sharma, N., Stevenson, J., Swanson, S. J., Tauer, K., Yang, S. C., Gregory, K., & Hughes, M.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2016-03
- Volume
- 14
- Issue
- 3
- Pages
- 255-264
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W2296139876
- Cited by
- 736
- References
- 306
- FWCI
- 74.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.